- Home
- AQMS vs IMNN Comparison
AQMS vs IMNN Comparison
Compare AQMS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- IMNN
- Stock Information
- Founded
- AQMS 2014
- IMNN 1982
- Country
- AQMS United States
- IMNN United States
- Employees
- AQMS N/A
- IMNN N/A
- Industry
- AQMS Metal Fabrications
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- IMNN Health Care
- Exchange
- AQMS Nasdaq
- IMNN Nasdaq
- Market Cap
- AQMS 11.1M
- IMNN 12.1M
- IPO Year
- AQMS 2015
- IMNN 1985
- Fundamental
- Price
- AQMS $1.15
- IMNN $0.60
- Analyst Decision
- AQMS Strong Buy
- IMNN Strong Buy
- Analyst Count
- AQMS 3
- IMNN 2
- Target Price
- AQMS $21.00
- IMNN $15.50
- AVG Volume (30 Days)
- AQMS 161.4K
- IMNN 237.6K
- Earning Date
- AQMS 05-08-2025
- IMNN 05-12-2025
- Dividend Yield
- AQMS N/A
- IMNN N/A
- EPS Growth
- AQMS N/A
- IMNN N/A
- EPS
- AQMS N/A
- IMNN N/A
- Revenue
- AQMS N/A
- IMNN N/A
- Revenue This Year
- AQMS N/A
- IMNN N/A
- Revenue Next Year
- AQMS $550.00
- IMNN N/A
- P/E Ratio
- AQMS N/A
- IMNN N/A
- Revenue Growth
- AQMS N/A
- IMNN N/A
- 52 Week Low
- AQMS $1.05
- IMNN $0.64
- 52 Week High
- AQMS $10.44
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- AQMS 41.16
- IMNN 24.71
- Support Level
- AQMS $0.93
- IMNN $0.60
- Resistance Level
- AQMS $1.05
- IMNN $1.08
- Average True Range (ATR)
- AQMS 0.11
- IMNN 0.08
- MACD
- AQMS -0.00
- IMNN -0.02
- Stochastic Oscillator
- AQMS 43.43
- IMNN 3.12
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).